Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

GBT021601

Aliases
open-label GBT021601

5 clinical trials

2 indications

Indication
Sickle Cell Disease
Indication
Renal Impairment
Clinical trial
A PHASE 1 STUDY TO ASSESS THE MASS BALANCE, EXCRETION, AND PHARMACOKINETICS OF [14C]-GBT021601, AN ORAL HEMOGLOBIN SPOLYMERIZATION INHIBITOR, IN HEALTHY PARTICIPANTS
Status: Completed, Estimated PCD: 2023-08-10
Clinical trial
An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial
Status: Recruiting, Estimated PCD: 2029-04-11
Clinical trial
A Phase I, Open-Label, Single-Dose, Non-Randomized, Parallel Group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of GBT021601, an Oral Hemoglobin S Polymerization Inhibitor, in Adult Participants With Renal Impairment
Status: Recruiting, Estimated PCD: 2024-10-04
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose (SAD/MAD) Study to Evaluate the Safety, Tolerability, PK, and Food Effect of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Healthy Participants.
Status: Completed, Estimated PCD: 2022-11-02
Clinical trial
An Intrapatient Single Dose and Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Participants With Sickle Cell Disease (SCD)
Status: Completed, Estimated PCD: 2022-12-06